Latest news for Rebus Hldgs (OTC:RBSH) Stock

Rebus Hldgs Inc is an early-stage, pre-revenue, pharmaceutical company that is focused on the development of prodrug cancer therapeutics for the treatment of disease. The company along with its subsidiaries is engaged in the production of small-molecule adenosine receptor modulators. Adenosine is an extracellular signaling molecule that regulates multiple aspects of tissue function and specifically plays a role in immunity and inflammation.

Rebus Hldgs Inc

News

CRWD

GOOG

GOOGL

MSFT

CrowdStrike Crash Was Major Factor In Google-Wiz Talks Failing; Sources Say Crash Played A Role

Shares of Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) are on watch Tuesday amidst reports of significant changes in its Echo devices business strategy and <a href="https://www.benzinga.com/news/earnings/24/07/39900892/visa-likely-to-report-higher-q3-earnings-these-most-accurate-analysts-revise-forecasts-ahead-of-ear">broader company initiatives.</a>
<a href="https://www.benzinga.com/markets/equities/24/07/39898236/jeff-bezos-era-downstream-impact-losing-its-mojo-amazon-ceo-andy-jassy-is-reportedly-rethinking-">Amazon&#8217;s Echo devices, </a>featuring the Alexa voice assistant, have not met financial expectations, leading to billions in losses. According to a <a href="https://www.wsj.com/tech/amazon-alexa-devices-echo-losses-strategy-25f2581a?mod=latest_headlines">Wall Street Journal report</a>, Amazon's strategy of selling Echo devices at low prices to drive sales on its e-commerce platform has resulted in over $25 billion in losses from 2017 to 2021. Customers primarily used Echo devices for free applications, such as setting alarms and checking the weather, rather than engaging in more profitable activities.
In response, Amazon&#8217;s CEO Andy Jassy is rethinking the business model and plans to introduce a paid tier for Alexa, aiming to turn around the losses. This change comes amidst skepticism from some engineers working on the project.
Despite these losses, an Amazon spokesperson highlighted the success of other ventures within the devices division, stating, &#8220;Hundreds of millions of Amazon devices are used by customers around the world and to us, there is no greater measure of success.&#8221;
What Else: Alongside this strategy shift, Amazon is integrating conversational generative AI into Alexa. The internal project, "Banyan," aims to introduce a premium version of Alexa with a subscription model, potentially costing around $5 monthly. This move is designed to better compete with new generative AI-powered chatbots from companies like Google and OpenAI.
Additionally, Amazon&#8217;s book business has experienced a resurgence, generating $16.9 billion in gross merchandise sales in the first ten months of 2022, showcasing varied performance across different sectors of the company.
Analyst Commentary: Analysts at JMP view Amazon&#8217;s 2024 Prime Day favorably and expect the event to drive durability in e-commerce sales and potentially improve margins through increased volume and fulfillment network utilization. JMP maintained a Market Outperform rating on Amazon with a $225 price target. Moreover, Morgan Stanley&#8217;s Research Analyst Brian Nowak remains optimistic about Amazon, citing AWS growth and the potential for improved North America profits. Nowak aligns with street estimates on total revenue for third-quarter and has set a new price target of $240, indicating a 30% upside.
AMZN Price Action: Amazon shares were trading 2.35% higher at $186.84 according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro. </a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/checkout/benzinga-pro-essential-2024?utm_source=BZprocontent072324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="552" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/23133932/AMZN-1024x552.png" alt="" class="wp-image-452152" style="width:471px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/23133932/AMZN-1024x552.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/23133932/AMZN-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/23133932/AMZN-768x414.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/23133932/AMZN.png 1101w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39914148/donald-trump-to-announce-a-strategic-bitcoin-reserve-crypto-bettors-think-its-unlikely-but">Donald Trump To Announce A Strategic Bitcoin Reserve? Crypto Bettors Think It&#8217;s Unlikely But Possible</a></li>
</ul>
Image Via Shutterstock.

Movers

AMZN

Amazon Shares Are Trading Higher: What You Need To Know

Editor&#8217;s note: This story has been corrected to reflect that Tesla received approval to use a steer-by-wire system in Canada. 
Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) will release its financial results for the second quarter, after the closing <a href="https://www.benzinga.com/quote/TSLA/earnings">bell on Tuesday, July 23</a>.
Analysts expect the Austin, Texas-based company to report quarterly earnings at 62 cents per share, down from 91 cents per share in the year-ago period. Tesla is expected to post revenue of $24.77 billion, compared to $24.93 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Canada recently granted the EV maker approval to use its steer-by-wire system in the country as required for testing. The technology, which does not meet the country's specification for minimum steering angle, is only available on the company's Cybertruck and not on any of its other offerings.
Tesla shares gained 5.2% to close at $251.51 on Monday.
Benzinga readers can access the latest analyst ratings on the<a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie"> Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Mizuho analyst Vijay Rakesh maintained a Neutral rating and raised the price target from $180 to $230 on July 12. This analyst has an accuracy rate of 78%.</li>
<li>Wedbush analyst Daniel Ives reiterated an Outperform rating with a price target of $300 on July 11. This analyst has an accuracy rate of 76%.</li>
<li>Goldman Sachs analyst Mark Delaney maintained a Neutral rating and boosted the price target from $175 to $248 on July 10. This analyst has an accuracy rate of 73%.</li>
<li>Truist Securities analyst William Stein maintained a Hold rating with a price target of $162 on July 3. This analyst has an accuracy rate of 88%.</li>
<li>New Street Research analyst Pierre Ferragu maintained a Buy rating with a price target of $235 on June 25. This analyst has an accuracy rate of 78%.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39881674/top-4-tech-stocks-that-may-explode-in-july">Top 4 Tech Stocks That May Explode In July</a></li>
</ul>

Earnings

Price Target

Markets

Analyst Ratings

Trading Ideas

TSLA

Tesla Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call (CORRECTED)

- Reuters Citing Message Read Aloud On Senate Floor

Macro Economic Events

Legal

Economics

U.S. Senate Has Received Resignation Of Senator Menendez

<a href="https://www.wsj.com/livecoverage/stock-market-today-earnings-dow-sp500-nasdaq-07-23-2024/card/perlmutter-sells-entire-disney-stake-after-proxy-fight-loss-BXemLjKEolk1S1EtJKhc?page=1">https://www.wsj.com/livecoverage/stock-market-today-earnings-dow-sp500-nasdaq-07-23-2024/card/perlmutter-sells-entire-disney-stake-after-proxy-fight-loss-BXemLjKEolk1S1EtJKhc?page=1</a>
Isaac "Ike" Perlmutter, the <a href="https://www.wsj.com/articles/disney-marvel-perlmutter-laid-off-fired-16821248">former Marvel Entertainment executive</a>, who for the last decade and a half has been one of Disney's largest independent shareholders, has sold his entire stake.
Perlmutter banded with activist investor Nelson Peltz <a href="https://www.wsj.com/articles/how-nelson-peltz-and-disneys-marvel-chief-teamed-up-in-proxy-fight-fcb1602f">last year in a campaign</a> to secure two seats on Disney's board of directors, contributing nearly 26 million shares to Peltz's war chest. In April, shareholders voted overwhelmingly in favor of Disney's slate, effectively endorsing CEO Bob Iger and his management team while handing Peltz and Perlmutter <a href="https://www.wsj.com/business/media/how-disneys-bob-iger-vanquished-wall-street-agitator-nelson-peltz-7f4760cc">a bruising defeat</a>.

Asset Sales

Management

Reported Earlier, 'Perlmutter Sells Entire Disney Stake After Proxy Fight Loss' - WSJ

Embecta Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>), a manufacturer of disposable <a href="https://www.benzinga.com/general/biotech/24/07/39732571/fda-rejects-novo-nordisks-weekly-insulin-requests-information-related-to-manufacturing-process-ty">insulin pen needles</a> and syringes, is considering a potential sale following a significant drop in its share price since being spun off from health tech giant Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>).
The medical technology company, which supplies approximately 8 billion syringes and needle pens annually across more than 100 countries, has engaged advisers from Centerview Partners <a target="_blank" href="https://www.benzinga.com/quote/embc" rel="noreferrer noopener">to explore a sale</a>.
Embecta&#8217;s share price has plummeted nearly 70% since its April 2022 spin-off, leaving the Nasdaq-listed firm valued at $2.1 billion.
The decline is attributed to several factors, including the impact of GLP-1 drugs such as Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic, reducing demand for traditional insulin treatments for type 2 diabetes.
Despite this, the Financial Times notes that Devdatt Kurdikar, Embecta&#8217;s CEO, remains optimistic, suggesting that the presence of GLP-1 drugs has only delayed, not eliminated, the need for insulin.
The company&#8217;s U.S. business, which generates about half of its revenue, has been particularly affected by the shift towards GLP-1 medications.
The FT <a target="_blank" href="https://www.ft.com/content/4aa65f0f-dcdf-4849-bd87-b81b23961fc1" rel="noreferrer noopener">report</a>, citing analysts, also notes that declining profit margins and the costs associated with separating from Becton Dickinson have negatively impacted Embecta&#8217;s stock performance.
For the fiscal year ending in September, Embecta&#8217;s adjusted net income is expected to decrease by 23% to $132 million, while annual revenues are projected to hold steady around $1.1 billion.
Despite the current challenges, Kurdikar points to potential growth opportunities, including increasing diabetes rates in developing regions where insulin remains the preferred treatment and the potential approval of a new insulin patch pump by the FDA, which could enhance the company&#8217;s growth prospects.
While a sale remains a possibility, the outcome is uncertain, and Embecta could continue as a listed entity.
Price Action: EMBC stock is up 7.18% at $16.27 at last check Tuesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39909352/cancer-focused-cellectar-biosciences-stock-trades-lower-despite-meeting-goal-in-blood-cancer-stud" target="_blank" rel="noreferrer noopener">Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study</a>.</li>
</ul>
Photo: Shutterstock

Health Care

Rumors

General

EMBC

Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off

Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) burn rates continue to stay elevated, making traders bullish on <a href="https://www.benzinga.com/money/shiba-inu-price-prediction">better price performance</a> to come.
What Happened: Shibburn data shows the burn rate surging by 1,947% in the past 24 hours, removing 60.2 million coins from the ecosystem. Three transactions involving 9.99 million coins each were reported around 16 hours ago. One transaction around 16 hours ago burned 10.16 million coins and another transaction one hour ago burned 1.25 million coins.
Shiba Inu has seen elevated burn rates over the past two weeks, burning 135.03 million coins in the past week. This comes after the Shiba Army requested Binance to have a daily burn mechanism for the meme coin.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39885387/is-dogecoin-killer-shiba-inu-on-a-bearish-path-whale-transactions-burn-rate-suggest-otherw">Is &#8216;Dogecoin Killer&#8217; Shiba Inu On A Bearish Path? Whale Transactions, Burn Rate Suggest Otherwise</a>
Why It Matters: IntoTheBlock data shows large transaction volume increased by 269% and daily active addresses dropped by 17.7%. Transactions greater than $100,000 spiked from 30 transactions as of July 21 to 75 transactions as of July 22.
Shiba Inu's marketing lead Lucie predicted bullish momentum for altcoins, specifically SHIB, SHEB, LEASH and BONE.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Meanwhile they fud and people fear BlackRock drops Ethereum ETF video for investors THINK BIG &#8211; Altcoin season is coming <a href="https://twitter.com/search?q=%24SHIB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHIB</a> <a href="https://twitter.com/search?q=%24SHEB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHEB</a> <a href="https://twitter.com/search?q=%24LEASH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$LEASH</a> <a href="https://twitter.com/search?q=%24BONE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BONE</a><a href="https://t.co/mTOgxA1oDM">pic.twitter.com/mTOgxA1oDM</a>
&mdash; 
</blockquote></div></figure>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$SHIB

'Dogecoin Killer' Shiba Inu Burn Rate Spikes 1,947% As Marketing Lead Predicts 'Altcoin Season'

<a href="https://www.bloomberg.com/news/articles/2024-07-23/nike-hires-former-salesforce-executive-as-chief-innovation-officer?utm_content=business&amp;utm_medium=social&amp;utm_campaign=socialflow-organic&amp;utm_source=twitter&amp;cmpid=socialflow-twitter-business&amp;sref=2h1zKciy" title="https://www.bloomberg.com/news/articles/2024-07-23/nike-hires-former-salesforce-executive-as-chief-innovation-officer?utm_content=business&amp;utm_medium=social&amp;utm_campaign=socialflow-organic&amp;utm_source=twitter&amp;cmpid=socialflow-twitter-business&amp;sref=2h1zKciy">https://www.bloomberg.com/news/articles/2024-07-23/nike-hires-former-salesforce-executive-as-chief-innovation-officer?utm_content=business&amp;utm_medium=social&amp;utm_campaign=socialflow-organic&amp;utm_source=twitter&amp;cmpid=socialflow-twitter-business&amp;sref=2h1zKciy</a>

'Nike Hires Former Salesforce Executive as CIO in Tech Division Shakeup' - Bloomberg

Last Thursday, Taiwan Semiconductor Manufacturing Company Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tsm#NYSE">TSM</a>) reported its second quarter results, surpassing both top and bottom-line estimates.&nbsp;Surging demand for advanced chips used for developing gen-AI applications has boosted Taiwan listed shares of the world&rsquo;s leading producer of&nbsp;advanced chips found in everything from smartphones to AI applications, whose clients are the titans Apple Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>)&nbsp;and Nvidia Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>), among others, by almost 70%&nbsp;year-to-date.
<h3>Second Quarter Highlights</h3>
Fueled by its exclusive partnerships with Apple and Nvidia, TSMC reported net revenue grew 40.1% YoY to 673.51 billion&nbsp;New Taiwan dollars ($20.82 billion), surpassing LSEG&rsquo;s consensus estimate of NT$657.58 billion.&nbsp;
For the June quarter,&nbsp;net income grew 36.3% YoY to NT$247.85 billion which is about&nbsp;$7.59 billion,&nbsp;also surpassing LSEG&rsquo;s consensus estimate of NT$238.8 billion.
Third quarter guidance shows continued growth is expected.
TSMC projects third-quarter revenue between $22.4 billion and $23.2 billion,&nbsp;which would represent growth of about 30% to 33%.
2024 is expected to be a strong growth year due to strong smartphone and AI-related demand. As for the annual capital budget, TSMC narrowed the range to between $30 billion and $32 billion, while it previously guided for $28 billion to $32 billion. 70% to 80% of the budget will be allocated to advanced technologies.
TSMC is not only benefiting from the AI hype, it is one of those helping to create it.
TSMC&rsquo;s latest financial results and optimistic forecasts paint a picture of a leading company at the forefront of the AI revolution, together with Nvidia, which it counts among its clients.&nbsp;Samsung Electronics and&nbsp;Intel Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intel#NASDAQ">INTEL</a>)&nbsp;are trying to challenge its dominance. While TSMC has been the world&rsquo;s first chip contract maker for years and world&rsquo;s biggest foundry, its earnings have long been lagging those of Intel, but in 2023, its revenue surpassed those of both Intel and Samsung. It also leads in the operating profit arena. But Intel, who led the industry for decades, is determined to make a comeback and go beyond just fabrication and assembly with an ambitious foundry strategy. Foundry competition is heading up but for now, TSMC is still leading the way and it has the best partners, Apple and Nvidia, on its side.
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

AAPL

INTEL

NVDA

TSMC's Latest Results Show It Is More Than A Beneficiary Of The AI Hype As It Is One Of One Its Creators

On Tuesday, Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) shared topline results from its Phase 2b/3 clinical trial (MK-1654-004) of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b39901907/merck-announces-topline-results-from-phase-2b3-trial-of-clesrovimab-mk-1654-an-investigational-res" rel="noreferrer noopener">clesrovimab (MK-1654)</a>.
Clesrovimab is the company&#8217;s investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease.
Clesrovimab met its primary safety and efficacy endpoints in the trial, including reducing medically attended lower respiratory infections (MALRI) caused by RSV through Day 150.
Participants were randomized to receive either a single dose of clesrovimab or a placebo.
Detailed study findings will be presented at an upcoming scientific congress, and Merck plans to file these data with global regulatory authorities.
Sanofi SA (NASDAQ:) /AstraZeneca Plc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Beyfortus (nirsevimab) received FDA approval <a target="_blank" href="https://www.benzinga.com/general/biotech/23/07/33262341/astrazeneca-sanofis-respiratory-syncytial-virus-treatment-scores-fda-approval-to-prevent-infectio" rel="noreferrer noopener">in June 2023</a> for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants.
Sanofi and AstraZeneca&nbsp;revealed data from a real-<a target="_blank" href="https://www.benzinga.com/general/biotech/23/05/32363375/sanofi-astrazeneca-release-real-world-data-for-respiratory-syncytial-virus-antibody" rel="noreferrer noopener">world trial in May 2023</a>.
The phase 3 HARMONIE study recruited over 8,000 infants 12 months and younger.
Infants who received a single dose of the antibody were 83% less likely to be hospitalized than those who <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38432249/drugmaker-sanofis-strong-dupixent-and-beyfortus-vaccine-sales-propel-q1-earnings" rel="noreferrer noopener">were not inoculated</a>.
Most recently, Japan&nbsp;approved&nbsp;Beyfortus (nirsevimab) for the prophylaxis of lower respiratory tract disease caused by respiratory syncytial virus in all neonates, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37966441/whats-going-on-european-pharma-giant-astrazeneca-stock-on-wednesday" rel="noreferrer noopener">infants, and children</a>.
Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) maternal RSV vaccine,&nbsp;Abrysvo, is available as a preventive <a target="_blank" href="https://www.benzinga.com/general/biotech/23/08/33983722/fda-greenlights-pfizers-rsv-vaccine-moms-can-now-protect-babies-before-birth" rel="noreferrer noopener">measure for young infants</a>.
It is advised to be given to women 32 to 36 weeks into a pregnancy to prevent lower respiratory tract infection and severe disease in infants until they are six months old.
Price Action: MRK stock is down 0.77% at $124.72 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39672069/pfizers-rsv-vaccine-abrysvo-clears-concerns-over-preterm-birth-risk-safety-for-pregnant-women-new" target="_blank" rel="noreferrer noopener">Pfizer&#8217;s RSV Vaccine Abrysvo Clears Concerns Over Preterm Birth Risk, Safety For Pregnant Women, New Study Shows</a>.</li>
</ul>
Photo Courtesy of Merck

Biotech

Large Cap

Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants

Internet Computer's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ICP</a>) price has decreased 7.27% over the past 24 hours to $9.63, continuing its downward trend over the past week of -0.0%, moving from $9.62 to its current price. 
The chart below compares the price movement and volatility for Internet Computer over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1721761422_0.png" alt="price_chart" />
The trading volume for the coin has fallen 47.0% over the past week which is opposite, directionally, with the overall circulating supply of the coin, which has increased 0.47%. This brings the circulating supply to 467.08 million. According to our data, the current market cap ranking for ICP is #27 at $4.50 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1721761422_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$ICP

Cryptocurrency Internet Computer Decreases More Than 7% Within 24 hours

Sen. J.D. Vance (R-Ohio) was selected to be Donald Trump's running mate in the 2024 presidential election, bringing a short political career into one of the most important political positions in <a href="https://www.benzinga.com/general/politics/24/07/39780777/trump-picks-senator-j-d-vance-as-running-mate-musk-says-great-choice-for-vp">the U.S.</a>
Prior to his political career, Vance was in the venture capital sector. Vance's time there is drawing more attention a week after Trump's announcement.
What Happened: Perhaps best known as the author of "Hillbilly Elegy," Vance's career as <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39799850/5-things-you-might-not-know-about-j-d-vance-hillbilly-elegy-author-bitcoin-holder-first-mi">an author and venture capitalist </a>may have collided.
Two months before the bestselling book came out, Vance moved to San Francisco to join Mithril Capital, a venture capital firm backed by Peter Thiel.
"It never seemed like he was even working," a former coworker <a href="https://www.businessinsider.com/jd-vance-venture-capitalist-colleagues-2024-7">told </a>Business Insider. "It felt like his full-time job was the book."
Former coworkers said Vance did not close a single deal a year after he started with the firm.
Vance has acknowledged his potential lack of contribution at Mithril.
"How useful I've been on that front is probably debatable," Vance said in a previous interview on his venture capital history.
Vance went on to work at Revolution, a venture capital firm founded by AOL founder Steve Case. While at Revolution, Vance was able to help close several deals investing in companies in the artificial intelligence and military tech sectors.
One former investor said they couldn&#8217;t recall what Vance &#8220;brought to the fund&#8221; while working at Revolution. 
His success at Revolution led to Vance founding his own venture capital firm Narya Capital in 2019. Among the investments made by Narya was one in video sharing platform Rumble Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>).
Read Also: <a href="https://www.benzinga.com/general/politics/24/07/39873381/trump-vp-pick-j-d-vance-worth-watching-for-potential-google-breakup-market-strategist-says-not-a">Trump VP Pick J.D. Vance &#8216;Worth Watching&#8217; For Potential Google Breakup, Market Strategist Says Not A Primary Concern With Trump Leading The Way</a>
Why It's Important: Most presidents and vice presidents come with backgrounds in law or politics. Vance was elected to the U.S. Senate in the 2022 election and served since early 2023.
Following in the footsteps of Trump, Vance could bring a business acumen to the White House with little political experience.
During Vance's run for Senate, venture capital expert Jeff Stohl was skeptical. Stohl, who is the director of the University of New Hampshire's Center for Venture Research, said there were "thousands of red flags" for Vance.
"You're either going to be a really great VC and a bad senator or a bad VC and a great Senator. Or what will likely happen is you're worse at both because you can't do both jobs," Stohl previously told Business Insider.
Vance's past venture capital ties could help Trump<a href="https://www.benzinga.com/news/24/07/39787707/peter-thiels-ties-with-jd-vance-may-influence-palantir-co-founders-position-on-trump-post-vp-selecti"> raise more money</a> in the 2024 election and could be behind several technology leaders endorsing the former president in the race.
Trump praised Vance's business career in technology and finance when announcing the senator as his running mate.
The former president also praised the bestselling book by Vance.
"Hillbilly Elegy became a major best-seller and movie, as it championed the hardworking men and women of our country," Trump said.
Vance was likely selected to be the vice-presidential pick for several reasons. Past venture capital experience appears to be a mixed bag of success and lack of contribution, according to first-hand testimonials.
Read Next:
<ul>
<li><a href="https://bzresearch.myclickfunnels.com/latest-research-webinar-redirect-evergreen?utm_source=website-content" target="_blank" rel="noreferrer noopener">Turn Trading Into The Ultimate Side Hustle Using Benzinga Tools In A Free Webinar</a></li>
</ul>
Photo: &#8220;Hillybilly Elegy&#8221; via First Edition; J.D. Vance by Consolidated News Photos via Shutterstock

Politics

J.D. Vance Venture Capital Background Under Scrutiny: 'It Never Seemed Like He Was Even Working, It Felt Like His Full-Time Job Was The Book'

Over the past 24 hours, Uniswap's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/uni/usd">UNI</a>) price has fallen 3.36% to $7.68. This continues its negative trend over the past week where it has experienced a 7.0% loss, moving from $8.2 to its current price. 
The chart below compares the price movement and volatility for Uniswap over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1721761353_0.png" alt="price_chart" />
The trading volume for the coin has decreased 41.0% over the past week, while the overall circulating supply of the coin has increased 0.02% to over 753.77 million. This puts its current circulating supply at an estimated 75.38% of its max supply, which is 1.00 billion. The current market cap ranking for UNI is #20 at $5.79 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1721761353_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$UNI

Uniswap Decreases More Than 3% Within 24 hours

Shiba Inu's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) price has decreased 3.92% over the past 24 hours to $0.000017, continuing its downward trend over the past week of -13.0%, moving from $0.000020 to its current price. 
The chart below compares the price movement and volatility for Shiba Inu over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1721761344_0.png" alt="price_chart" />
The trading volume for the coin has decreased 53.0% over the past week, while the overall circulating supply of the coin has increased 0.02% to over 589.26 trillion. The current market cap ranking for SHIB is #15 at $10.03 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1721761344_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Shiba Inu Down More Than 3% Within 24 hours

During the last three months, 6 analysts shared their evaluations of Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Equinix, presenting an average target of $845.0, a high estimate of $922.00, and a low estimate of $671.00. Surpassing the previous average price target of $826.50, the current average has increased by 2.24%.
<img src="https://www.benzinga.com/files/images/story/2024/1721761333_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Equinix by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$875.00</td>
<td>$825.00</td>
</tr>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Outperform</td>
<td>$873.00</td>
<td>-</td>
</tr>
<tr>
<td>James Schneider</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$870.00</td>
<td>-</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$671.00</td>
<td>$669.00</td>
</tr>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$922.00</td>
<td>$950.00</td>
</tr>
<tr>
<td>Michael Elias</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$859.00</td>
<td>$862.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Equinix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Equinix compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Equinix's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Equinix's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EQIX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Equinix analyst ratings.</a>
<h2>Get to Know Equinix Better</h2>
Equinix operates 260 data centers in 71 markets worldwide. It generates 44% of total revenue in the Americas, 35% in Europe, the Middle East, and Africa, and 21% in Asia-Pacific. The firm has more than 10,000 customers, including 2,100 network providers, that are dispersed over five verticals: cloud and IT services, content providers, network and mobile services, financial services, and enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from interconnection. Equinix operates as a real estate investment trust.
<h3>Equinix: Financial Performance Dissected</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Equinix's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.46% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Equinix's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 10.86%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Equinix's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.86%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Equinix's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.72%, the company showcases efficient use of assets and strong financial health.
Debt Management: Equinix's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.4.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EQIX

Analyst Expectations For Equinix's Future

Ratings for HBT Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBT#NASDAQ">HBT</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for HBT Finl, presenting an average target of $24.0, a high estimate of $27.00, and a low estimate of $21.00. Surpassing the previous average price target of $22.38, the current average has increased by 7.24%.
<img src="https://www.benzinga.com/files/images/story/2024/1721761325_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of HBT Finl's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Nathan Race</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$21.50</td>
</tr>
<tr>
<td>Damon Delmonte</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>David Long</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$23.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to HBT Finl. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of HBT Finl compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of HBT Finl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into HBT Finl's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HBT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on HBT Finl analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into HBT Finl's Background</h2>
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
<h3>Financial Insights: HBT Finl</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining HBT Finl's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -3.95% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: HBT Finl's net margin is impressive, surpassing industry averages. With a net margin of 29.42%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): HBT Finl's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.09%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): HBT Finl's ROA stands out, surpassing industry averages. With an impressive ROA of 0.3%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.21.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On HBT Finl Through 5 Analysts

Editor&#8217;s note: Benzinga first reported the Stellantis recall detailed in this story <a href="https://www.benzinga.com/news/24/07/39847767/stellantis-us-recalls-plug-in-hybrid-minivans-due-to-fire-risks">on July 18</a>. 
Stellantis NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) is recalling nearly 20,000 of its Pacifica Plug-In <a href="https://www.benzinga.com/news/24/07/39788586/former-ford-ceo-says-gms-hybrids-will-not-hit-market-for-another-couple-years-getting-mass-adoption">hybrid vehicles (PHEVs)</a> in the U.S. over concerns that its battery pack may cause a vehicle fire when parked, even when the ignition is switched off.
What Happened: The recall population includes 15,910 model year 2017-2018 and 3,606 model year 2019-2021 Pacifica PHEVs. The vehicles may experience a short within the battery pack which could cause a vehicle fire, the U.S. auto safety regulator National Highway Traffic Safety Administration (NHTSA) said on Tuesday. 
Certain Chrysler Pacifica plug-in hybrid minivans were recalled in early 2022 over similar concerns and issued a fixed. However, the company received more reports of fire despite the fix, confirming that the remedy deployed was not effective, necessitating a fresh recall. 
The company has identified four injuries potentially related to this issue for all markets but no accidents, Stellantis said in a filing with the NHTSA.
Fix And Repair: As for a solution, dealers will update the high-voltage Battery Pack Control Module with revised software or replace the battery pack assembly if needed, it added.
Until the fix is deployed, however, Stellantis warned the affected vehicle owners to not charge their vehicles but to park them away from other vehicles and structures. 
Earlier this month, <a href="https://www.benzinga.com/news/24/07/39708284/stellantis-recalls-more-than-341k-vehicles-over-concerns-of-airbag-non-deployment-incorrect-pressure">Stellantis recalled 332,000 vehicles in the U.S. </a>over concerns that a seat belt buckle switch sensor may be improperly connected, preventing the front seat airbag from deploying.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39899497/spacex-bags-113m-nasa-contract-to-launch-satellite-system-for-monitoring-earths-environment" target="_blank" rel="noreferrer noopener">SpaceX Bags $113M NASA Contract To Launch Satellite System For Monitoring Earth's Environment</a></li>
</ul>
Photo courtesy: Stellantis

Tech

STLA

Stellantis Recalls Nearly 20,000 Pacifica PHEVs Over Battery Fire Risks (UPDATED)

Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Xometry, presenting an average target of $21.0, a high estimate of $27.00, and a low estimate of $13.00. Experiencing a 22.22% decline, the current average is now lower than the previous average price target of $27.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1721761317_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Xometry is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Troy Jensen</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Underweight</td>
<td>$13.00</td>
<td>-</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Greg Palm</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Xometry. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Xometry compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Xometry's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Xometry's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/XMTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Xometry analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Xometry</h2>
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of the revenue is earned from the U.S. segment.
<h3>Financial Milestones: Xometry's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Xometry showcased positive performance, achieving a revenue growth rate of 16.49% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Xometry's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -13.54%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Xometry's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -5.11%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Xometry's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.37%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Xometry's debt-to-equity ratio is below the industry average. With a ratio of 0.93, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

XMTR

The Analyst Verdict: Xometry In The Eyes Of 4 Experts

During the last three months, 13 analysts shared their evaluations of IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for IQVIA Hldgs, revealing an average target of $265.62, a high estimate of $300.00, and a low estimate of $230.00. This upward trend is evident, with the current average reflecting a 0.58% increase from the previous average price target of $264.08.
<img src="https://www.benzinga.com/files/images/story/2024/1721761285_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of IQVIA Hldgs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$292.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$270.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$251.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$235.00</td>
<td>$241.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$270.00</td>
<td>-</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$292.00</td>
<td>$297.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$254.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to IQVIA Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of IQVIA Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of IQVIA Hldgs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of IQVIA Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IQV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on IQVIA Hldgs analyst ratings.</a>
<h2>Get to Know IQVIA Hldgs Better</h2>
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
<h3>Unraveling the Financial Story of IQVIA Hldgs</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: IQVIA Hldgs displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 2.33%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: IQVIA Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.71% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.62%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): IQVIA Hldgs's ROA stands out, surpassing industry averages. With an impressive ROA of 1.08%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: IQVIA Hldgs's debt-to-equity ratio stands notably higher than the industry average, reaching 2.17. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IQVIA Hldgs Stock: A Deep Dive Into Analyst Perspectives (13 Ratings)

Bitcoin Cash's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bch/usd">BCH</a>) price has decreased 7.27% over the past 24 hours to $365.57, continuing its downward trend over the past week of -7.0%, moving from $390.12 to its current price. 
The chart below compares the price movement and volatility for Bitcoin Cash over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1721761275_0.png" alt="price_chart" />
The trading volume for the coin has fallen 22.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has decreased 0.15%. This brings the circulating supply to 19.74 million, which makes up an estimated 93.98% of its max supply of 21.00 million. According to our data, the current market cap ranking for BCH is #18 at $7.22 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1721761275_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Rebus Hldgs

News

Latest news for Rebus Hldgs (OTC:RBSH) Stock